WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL …

www.wjpps.com Vol 9, Issue 6, 2020.

673

Suresh et al. World Journal of Pharmacy and Pharmaceutical Sciences

EPIDEMIC 2019-20 - COVID-19 CURRENT SCENARIO

Rajni Sawanny1, Deepa Bajetha

1, Vikas Sharma

1 and Suresh Kumar Joshi

2*

1Noida Institute of Engineering and Technology (Pharmacy Institute), Plot

No. 19,

Knowledge Park-II Institutional area Greater Noida, Uttarpradesh- 201306 India.

2Amerise Pharmaceuticals Pvt. Ltd, Ahmedabad, Gujarat, Pin-380060, India.

ABSTRACT

As per World Health Organization (WHO) viral ailments continued to

develop and affect a serious issue on the populace. most recent twenty

year’s numerous viral plagues like respiratory disorder coronavirus

(SARS-COV) in 2002 – 2003, H1N1 flu in 2009 have been archived,

as of late Middle East respiratory disorder coronavirus (MERS-COV)

was first seen in Saudi Arabia in 2012. At present bottomless

unexplored low respiratory diseases cases recognized in Wuhan, the

broad metropolitan territory in China's Hubei region, was first

answered to the WHO Country Office in China, on December 31,

2019. The causative specialist isn't distinguished at this point, first case is "pneumonia of

obscure etiology." The Chinese Center for Disease Control and Prevention (CDC) and

neighborhood CDCs requested an extreme episode examin On Feb 11, 2020 the WHO

Director-General, Dr. Tedros Adhanom Ghebreyesus pronounce that the infection brought

about by this new CoV was a "COVID-19,". By SARS-CoV broad scourge starting in China

and influence two dozen countriesaround 8000 cases and 800 passings, and the MERS-CoV

that started in Saudi Arabia and has around 2,500 cases and 800 passings and still causes rare

cases.

KEYWORDS: SARS-CoV, Pandemic, GDP, CDC etc.

INTRODUCTION

In current scenario COVID-19 arises as a headache in entire world, which is an infectious

disease caused by a newly discovered coronavirus. The spotting and spreading of respiratory

pathogen and its power and potential to outspread in human population acrimony (severity

WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES

SJIF Impact Factor 7.632

Volume 9, Issue 6, 673-697 Review Article ISSN 2278 – 4357

WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES

SJIF Impact Factor 7.632

Volume 9, Issue 6, XXX-XXX Review Article ISSN 2278 – 4357

Article Received on

15 April 2020,

Revised on 05 May 2020,

Accepted on 25 May 2020

DOI: 10.20959/wjpps20206-16332

*Corresponding Author

Suresh Kumar Joshi

Amerise Pharmaceuticals

Pvt. Ltd, Ahmedabad,

Gujarat, Pin-380060, India.


674


and harmfulness of a disease). It is spotted in 2019(COVID-19) coronavirus disease 2019,1st

detected in Wuhan City, in China December 2019.[1]

This new infection is transmittable and spread out quickly all over , this flare-up was reported

by the WHO a Public Health Emergency of International Concern (PHEIC) in light of the

fact that it spread to 18 nations with 4 nations recorded human to human transmission. It has

know become a main pathogen of respiratory ailment episode, International Committee on

Taxonomy of Viruses (ICTV) titled it the SARS-CoV-2 infection as it is identified with the

one that caused the SARS flare-up (SARS-CoVs).

They are an enormous group of single-stranded RNA infections (+ssRNA) disconnected from

unmistakable creature species. They can likewise disregard species obstructions and prompt

ailment from normal virus to progressively genuine respiratory issue and malady MERS and

SARS. Later these infection are no doubt started in bates and afterward move to different

warm blooded creatures or host - the Himalayan palm civet for SARS-CoV, and the

dromedary camel for MERS-CoV — before move to people or host. This virus is capable to

grow and become epidemic a severe public health risk issue. World government are work to

establish antidotes for this decimate effects of virus, health organizations provide guidance,

instruction’s, flow chat, posters to relieve or alleviate the effects and impression of this risk.

The virus came in contact with the host and the host connect with the surrounding and effect

all others by shaking hands, hug, sneeze, touching utensils etc. To avoid spreading this

infected host must avoid crowded areas such as, meetings, malls, office, schools, markets etc.

and quarantine himself.[2]

Etiology

The viral genome investigation starting report recognize that infection shares 88%

arrangement like two terrible inferred extreme intense respiratory disorder (SARS) like

coronavirus yet altogether different from serious intense respiratory disorder coronavirus

(SARS-CoV). Extraordinarily; homology demonstrating disclose that 2019-nCoV had the

same receptor-restricting area structure to that of SARS-CoV, in spite of amino corrosive

variety at some key deposits.[3]

So for the time being it’s called extreme intense respiratory disorder coronavirus (Harsco).

crown infection is bounded(enveloped) and single standard ribonucleic corrosive named for

its sun oriented crown like similarity by reason of 9-12 nm-long surface spikes. The


675


measurement of infection partials is lie within the range between 60–140 nm and show

circular shape with surprising or some pleomorphic.[4]

Table 1: First strain of COVID-19 - Basic information[4]

Descriptors Description

Name C-Tan-nCoV Wuhan Strain

Scientific classification Novel β genus coronavirus

Wellspring of the Specimen Clinical Patients

Wellspring of Collection Wuhan, Hubei Province, China

Confinement Date Jan 6, 2020

Hazard Level BSL-3

Beta coronavirus S proteins are prepared into S1 and S2 subunits by have proteases.[5]

Among 4 significant basic proteins encoded by corona viral genome on the envelope, in

which on is spike (S) protein partner with the cell receptors (angiotensin-changing over

catalyst 2 (ACE2)) to impact target cells and disease happen by this combination among

envelope and host cell film and viral enter in have cell. Hostile to ACE2 yet not against

ACE1 counter acting agent blocked viral replication on Vero E6 cells, show that ACE2 is a

utilitarian receptor for SARS-CoV.[6,7,8]

On Febrary11, 2020, the Coronavirus Study Group (CSG) of the International Committee on

Taxonomy of Viruses, at long last reason that it is a genuine respiratory disorder coronavirus

2 (SARS-CoV-2) and characterize infection and taxa of ―Coronaviridae‖ family dependent on

phylogeny, scientific classification and set up training. The CGS relize that thios infection is


676


like (SARS-CoVs) extreme intense respiratory disorder coronaviruses assigns it as serious

intense respiratory disorder coronavirus 2 (SARS-CoV-2). For additional comprehension of

host – infection communication explore are in procedure to improve readiness for future out

breaks.[9]

WHO named the illness instigate by this coronavirus as Coronavirus Disease 2019

(COVID-19).[10]

This flare-up is briefly connected with a fish advertise in Wuhan, China, where offer of wild

creatures may be source and root of zoonotic contamination. at present information it is see

that bat might be facilitated by COVID-19 may transmit to vertebrates by pangolin, it is

believing that pangolins are have for novel human infection ought to be disconnect from wet

markets to forestall zoonotic transmission. coronavirus similar to 2019-nCoV isolated from

a Rhinolophus affinis bat in Yunnan in 2013 has currently identified , closely related viruses

are not identified in other wildlife species.[11,12]

After investigate the virome design and

formation of pangolins (mammalian order Pholidota). They are increasingly influence and

now are in interest because they are illegally trafficked of any group of mammal: us e as food

source and traditional Chinese medicine. The novel pangolin coronavirus genomes have

around 85.5% to 92.4% similar to 2019-nCoV.[11]

To think about the developmental connection between SARS-CoV and its subordinates, 225

bats were gathered from Zhoushan city, Zhejiang territory, China, somewhere in the range of

2015 and 2017. PCR enhancement of the coronaviral protein RdRp distinguished

coronaviruses in 19.65% of bats of this district, and there tally was influenced via occasional

changes.by genomic investigations of the 2 new SL-CoVs (SARS-like coronaviruses)from

Zhoushan (ZXC21 and ZC45) uncover that their genomes were 29,732 nucleotides (nt) and

29,802 nt long, individually, with 13 open understanding edges (ORFs). this assessment

extend our keenness on the hereditary assorted variety of the SL-CoVs move by bats and give

a present perspective to examin the possibility of cross-species transmission of SL-CoVs

utilizing suckling rodents as a creature model. Flopped in confining the infection PCR-

positive examples in Vero E6 cells, they attempt to seclude infection from suckling rodents

by tainting them with tissue tests that were sure for the coronavirus. Following 14-15 days

obsessive investigations uncover that the incendiary response in the cerebrum tissues was

generally apparent and clear, the effect on the 10 suckling rodents are 4 show clinical side

effects, for example, sleepiness , moderate movement and mental wretchedness different

apoptotic neurons were found in the central regions of the mind tissue, and the chromatin in


677


the cores was consolidated and hazy.[13]

different radiological assessments, for example,

slender cut chest CT assume a huge job in clashing and battling against irresistible disease.[14]

Likewise early stage lung disease analyze by Chest CT,[15]

conspicuous general wellbeing

observation and reaction frameworks.[16,17]

Table 2: Chest ct findings are disclosed of covid-19.[15,16,17]

CT findings Frequency (%)

Ground-glass haziness 86

Consolidation 28

Crazy-paving 19

Liner 14

Cavitation 0

Discrete nodules 0

Bilateral distribution 76

Peripheral distribution 33

Clinical Symptom’s, Characteristics of 2019 Novel Coronavirus Infection

Clinical symptoms intellect is very crucial, though they are recommended indefinite or non

specific. most common symptoms are fever, cough, myalgia or fatigue, tiredness, difficulty

in breathing ( in severe cases) those which have weak immune systems might suffer from

severe symptoms such as pneumonia or bronchitis, symptoms are might not identify after

being exposed to COVID-19. Many conform cases are observe in adults few in childrens,

there is no evince that children are in high risk for this virus. Other hand diarrhea have an

unusual data on, 1,099 patients with laboratory-confirmed 2019-nCoV ARD from 552

hospitals in 31 provinces/provincial municipalities through January 29th, 2020. The disease

intensity (addition to oxygen saturation, respiratory rate, chest X-ray/CT manifestations and

blood leukocyte/lymphocyte count) predict unsatisfactory clinical result. Laboratory findings,

signs and clinical symptoms extrat from electronic medical records. Radiologic estimates

chest X-ray or computed tomography. Laboratory calculations conclude the result of blood

chemistry, coagulation test, blood count, liver function, electrolytes, renal fuction, creatine

kinase, creatine kinase., creatine kinase, procalcitonin and lactate dehydrogenase.[18,19]

The clinical outcomes are the % of patients admit in the ICU necessitating ventilation and the

% of death are 5.00%, 2.18% and 1.36%, respectively,[19]

few patients suffer from headache

or hemoptysis[20]

and asymptomatic.[21]

older mans are more affected and have respiratory

failure as a result severe alveolar damage, even fatal respiratory diseases like acute

respiratory distress syndrome.. By imaging examination 70% patents show bilateral


678


pneumonia, 12% show multiple mottling and ground-glass opacity and 1% patient show

pneumothorax. 16% identify with acute respiratory distress syndrome amongst them 10%

patients worsen a short period of time and died of multiple organ failure, it more likely affect

older males with comorbidities. Few patients died with the MuLBSTA score, it is an early

warning model foresee mortality in viral pneumonia. Research are in process to investigate

applicability of the MuLBSTA score in foresee the risk of mortality in 2019-nCoV

infection.[22]

Huge population infected most are men (70%) and have hypertension , cardiovascular and

diabetes, and symptoms observe are Dyspnoea , sputum production, lymphopenia also

pneumonia with abnormal findings on chest CT. some Complications are acute respiratory

distress syndrome, RNAaemia, acute cardiac injuryand secondary infections patients were

admitted to an ICU and 10% died.in comparative with NON-ICU patients higher plasma

levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFα observe in ICU patients. A

batch or collection of severe respiratory illness occur by novel 2019-nCoV infection.[23]

Patients may show normal or less white blood cell counts, lymphopenia, or

thrombocytopenia, with prolonged activated thromboplastin time and rise C-reactive protein

level. In short, patients suffering from fever and upper respiratory tract symptoms with

lymphopenia or leukopenia should be suspect mostly in patients with Wuhan disclosure or

close contact history.[21,22,23].

Diagnosis of COVID-19

Early stages symptoms are non – specific, some common respiratory disorders from different

diagnosis might be infectious or non -infectious are Adenovirus, Influenza, Human

metapneumovirus (HmPV), Parainfluenza, Rhenovirus and Respiratory syncytial

virus(RSV).[2]

Clinical diagnosis is done by Radiology and CT imaging findings, first the

clinical diagnostic workflow should be there to confirm Wuhan exposure history or close

contact , connection with people from Wuhan or confirmed patients from last few weeks.

WHO recommends and collect samples of upper and lower respiratory tracts accomplish

through expectorated sputum, broncho alveolar lavage, or endotracheal aspirate then samples

are estimate for viral RNA by using polymerase chain reaction (PCR). If positive test observe

then test is repeat for re- verification, if test is negative with strong clinical suspicion also

warrants for repeat testing for accurate results and confirmation.[24]

U.S. CDC set rules and

criteria for persons under investigation (PUI).[2]

in (PUI) instant prevention and infection


679


control measures are taken. Various Epidemiological factors are used for testing purpose.[24]

there are many patients have no evidence and unknown exposure history rising due to rapid

spread of virus. The National Health Commission of China start Diagnosis and Treatment

Program of 2019 New Coronavirus Pneumonia (trial sixth version) (fig. 3) with the

guidelines given by (WHO) world health organization on (SARS) and (MERS),[27,28]

and

arranged experts to analyze , judge , and summarize the initial work of treatment and modify

it.[26]

MERS-CoV also extracted from the patient and the camel. The overall genome

sequences of the two isolates are similar mortal case of human MERS-CoV infection was

transfer through close contact with an infected camel.[27]

If patient have exposure history and

clinical conditions is consider as a suspected case, if no exposure history but have 2or 3

clinical conditions then it is conclude a suspected patient(fig 2).on the basis of (fifth trial

version).[29]

The clinical diagnosis of COVID-19 infection confirmation and manifest are

chest CT findings of viral pneumonia. though, WHO not believe or accept CT without RT-

PCR evidence till February, 17, 2020.[30]

The clinical diagnosis term is removed in currently

published Diagnosis and Treatment Program of 2019 New Coronavirus Pneumonia (trial

sixth version).[28]

the last examination or diagnosis of COVID-19 is important this is later

confirm by positive real-time polymerase chain reaction ( RT-PCR ) assay for COVID-19

with the help of respiratory and blood samples or by viral gene sequencing of respiratory or

blood samples which are greatly equivalent to COVID-19. On the basis of clinical

symptoms confirmed patients are separated in to mild, moderate, severe, and acute or critical

types (table 3).[28,31,32]

Table 3: Standard for clinical severity of conform cases of COVID-19 coronavirus

disease 2019 pneumonia, data from.[28,31,32]

Types Findings

Mild Mild clinical symptoms [fever<37°C(quelled without treatment) with or

without cough no dyspnea, no grasping , no chronic disease], no imaging

findings of pneumonia

Moderate Fever, respiratory symptoms and imaging findings of pneumonia

Severe Meet any of following: Meet respiratory distress, RR≥30times/min

Spo2 <93% at rest

Pao2/ Fio2≤ 300 mmHg

Critical Meet any of following : Respiratory failure need mechanical assistance

Shock

―Extra pulmonary‖organ failure, intensive care unit is needed

Patients showing rapid progression (>50%) on CT imaging with in 24-48

hrs should mange as severe(trail sixth edition)


680


Fig. 2: coronavirus case by Chinese Health Commission.

Pathophisology

Coronaviruses are sure positive strand RNA infections that cause malady in people, and

residential and buddy creatures. CoVs are encompassed /enveloped, positive-stranded RNA

infections with nucleocapsid. They are generally famous for causing extreme intense

respiratory disorder (SARS) episodes in 2002–2003[2,33]

All coronaviruses follow a similar

essential system of replication. All coronaviruses encode 15 or 16 replicase related proteins, 4

or 5 basic proteins and 1–8 gathering explicit or adornment proteins. A considerable lot of the

replicase proteins are gathered into replication hardware in twofold film vesicles (DMVs) and

on a reticular system of layers that are gotten from the endoplasmic reticulum. In numerous

coronavirus contaminations, ailment seriousness increments during infection leeway,

proposing that the host invulnerable reaction is both defensive and pathogenic. Moreover,

hindrance of explicit parts of the resistant reaction brings about less serious infection and less

tissue obliteration, without reducing the energy of infection leeway. Like all fruitful

infections, coronaviruses have advanced both uninvolved and dynamic instruments to avoid

the interferon reaction. Replication in DMVs may add to uninvolved avoidance of the natural

resistant reaction by making twofold stranded RNA out of reach to cell sensors.[33]

Coronaviruses picked up unmistakable quality during the extreme intense respiratory disorder

(SARS) episodes of 2002–2003.[34]

The viral film contains the transmembrane (M)


681


glycoprotein, the spike (S) glycoprotein and the envelope (E) protein, and encompasses a

cluttered or adaptable, most likely helical, nucleocapsid. The viral film is surprisingly thick,

most likely in light of the fact that the carboxy-terminal locale of the M protein shapes an

extra inside layer, as uncovered by cryo-electron tomography. Coronaviruses are isolated into

three gatherings, and further subdivided into subgroups, dependent on serologic, and all the

more as of late on hereditary, examinations. With the ID of all the more indirectly related

infections, the scientific classification of these infections is probably going to experience

further changes.[35,36]

For tending to pathogenetic components of SARS-CoV-2, its viral

structure, and genome must be contemplations. In CoVs, the genomic structure is composed

in a +ssRNA of roughly 30 kb long — the biggest known RNA infections — and with a 5′-

top structure and 3′-poly-A tail. Beginning from the viral RNA, the combination of

polyprotein 1a/1ab (pp1a/pp1ab) in the host is figured it out. The interpretation works

through the replication-translation complex (RCT) sorted out in twofold layer vesicles and by

means of the combination of subgenomic RNAs (sgRNAs) arrangements. Of note, translation

end happens at interpretation administrative successions, situated between the alleged open

understanding casings (ORFs) that fill in as layouts for the creation of subgenomic mRNAs.

In the atypical CoV genome, in any event six ORFs can be available. Among these, a

frameshift somewhere in the range of ORF1a and ORF1b guides the creation of both pp1a

and pp1ab polypeptides that are handled by virally encoded.

Fig. 3: Arrangement /framework of coronavirus genome and virion.

a. Schematic outline of delegate genomes from each of the coronavirus gatherings. Around

the initial 66% of the 26–32 Kb, positive-sense RNA genome encodes a huge polyprotein

(ORF1a/b; green) that is proteolytically separated to create 15 or 16 non-auxiliary


682


proteins (nsps; nsps for extreme intense respiratory disorder coronavirus (SARS-CoV) are

outlined). The 3′-end third of the genome encodes four basic proteins — spike (S), film

(M), envelope (E) and nucleocapsid (N) (all appeared in blue) — alongside a lot of extra

proteins that are novel to every infection species (appeared in red). Some gathering 2

coronaviruses express an extra basic protein, haemagglutinin -esterase (not appeared).

b. Schematic outline of the coronavirus virion. 2′OMT, ribose-2′-O-methyltransferase;

ExoN, 3′→5′ exonuclease; Hel, helicase; IBV, contamination bronchitis infection;

NendoU , uridylate -explicit endoribonuclease; RDRP, RNA-subordinate RNA

polymerase; ssRBP, single-stranded RNA restricting protein; ssRNA, single-stranded

RNA; TGEV, transmissible gastroenteritis infection.

Chymotrypsin-like protease (3CLpro) or fundamental protease (Mpro), just as a couple of

papain-like proteases for delivering 16 non-basic proteins (nsps). Aside from ORF1a and

ORF1b, different ORFs encode for basic proteins, including spike, film, envelope, and

nucleocapsid proteins[37]

A subset of gathering 2 coronaviruses encode an extra

haemagglutinin - esterase (HE) protein (Fig 3). The HE protein, which might be engaged

with infection passage or departure, isn't required for replication, yet seems, by all accounts,

to be significant for contamination of the regular host.[38]

Pathophysiology and

destructiveness mechanisms of CoVs, and consequently likewise of SARS-CoV-2 have

connections to the capacity of the nsps and auxiliary proteins. For example, inquire about

underlined that nsp can hinder the host natural insusceptible reaction. Among elements of

basic proteins, the envelope has a vital job in infection pathogenicity as it advances viral get

together and discharge. Nonetheless, a considerable lot of these highlights (e.g., those of nsp

2, and 11) have not yet been portrayed. Among the auxiliary components of CoVs, there are

the spike glycoproteins made out of two subunits (S1 and S2). Homotrimers of S proteins

form the spikes on the viral surface, controlling the connection to have receptors.[39,40]

Of note, in SARS-CoV-2, the S2 subunit — containing a combination peptide, a

transmembrane area, and cytoplasmic space — is profoundly rationed. Therefore, it could be

an objective for antiviral (hostile to S2) mixes. Despite what might be expected, the spike

receptor-restricting area presents just a 40% amino corrosive character with different SARS-

CoVs. Other auxiliary components on which research should fundamentally center are the

ORF3b that has no homology with that of SARS-CoVs and a discharged protein (encoded by

ORF8), which is basically not quite the same as those of SARS-CoV[41,33]

In global quality

banks, for example, GenBank, specialists have distributed a few Sars-CoV-2 quality

arrangements. This quality mapping is of key significance permitting scientists to follow the

phylogenetic tree of the infection and, most importantly, the acknowledgment of strains that


683


contrast as indicated by the changes. As indicated by late research, a spike transformation,

which likely happened in late November 2019, activated bouncing to people. Specifically,

Angeletti et al. looked at the Sars-Cov-2 quality grouping with that of Sars-CoV. They

examined the transmembrane helical fragments in the ORF1ab encoded 2 (nsp2) and nsp3

and found that position 723 presents a serine rather than a glycine buildup, while the position

1010 is involved by proline rather than isoleucine. The matter of viral transformations is key

for clarifying potential infection backslides.[41]

The matter of viral changes is key for clarifying potential infection backslides. Research will

be expected to decide the basic attributes of SARS-COV-2 that underlie the pathogenetic

systems. Contrasted with SARS, for instance, starting clinical information show less extra

respiratory association, albeit because of the absence of broad information, it is beyond the

realm of imagination to expect to draw authoritative clinical data. The pathogenic instrument

that produces pneumonia is by all accounts especially mind boggling. Clinical and preclinical

research should clarify numerous perspectives that underlie the specific clinical introductions

of the sickness. The information so far accessible appear to demonstrate that the viral

contamination is equipped for delivering an over the top resistant response in the host. Now

and again, a response happens which all in all is named a 'cytokine storm'. The impact is

broad tissue harm. The hero of this tempest is interleukin 6 (IL-6). IL-6 is created by enacted

leukocytes and follows up on countless cells and tissues. It can advance the separation of B

lymphocytes, advances the development of certain classes of cells, and restrains the

development of others. It additionally invigorates the creation of intense stage proteins and

assumes a significant job in thermoregulation, in bone upkeep and in the usefulness of the

focal sensory system. Despite the fact that the fundamental pretended by IL-6 is expert

provocative, it can likewise have mitigating impacts. Thus, IL-6 increments during fiery

ailments, contaminations, immune system issue, cardiovascular infections and a few kinds of

malignancy. It is likewise involved into the pathogenesis of the cytokine discharge disorder

(CRS) that is an intense fundamental fiery disorder described by fever and various organ

brokenness[2,40,41,42]

Mechanism/System of coronavirus replication and translation

The N protein is significant for encapsidation of viral RNA and goes about as an interferon

(IFN) rival (see underneath). Moreover, it causes upregulation of FGL2, a prothrombinase

that adds to lethal hepatic sickness in mice that are contaminated with MHV-3.[43]

and that


684


alters changing development factor-β (TGFβ) motioning in SARS-CoV-tainted cells.[44]

The

E proteins are little indispensable layer proteins with jobs in infection morphogenesis, get

together and maturing. Without E proteins, infection discharge is restrained totally (on

account of transmissible gastroenteritis infection (TGEV)) or somewhat (on account of

SARS-CoV and MHV).[45,46,47]

The E protein likewise has particle channel action, which is

required for ideal infection replication.[48,49]

Scattered between and in these auxiliary qualities are one to eight qualities that encode

adornment proteins, contingent upon the infection strain. These show no grouping similitude

with other viral or cell proteins and are not required for infection replication in refined

cells.[50,51,52]

In any case, they are moderated in infection species secluded at various

occasions and regions (for instance, for SARS-CoV).[53]

which recommends that these

proteins have a significant job in replication in the regular host. A few accessory proteins are

virion-related[54,55,56,57]

despite the fact that whether these proteins are genuinely basic is

disputable.[58]

The genes that encode non-replicase proteins are expressed from a set of

'nested' subgenomic mRNAs that have common 3′ ends and a common leader that is encoded

at the 5′ end of genomic RNA. Proteins are produced generally only from the first ORF of

subgenomic mRNAs, which are produced during minus strand RNA synthesis. Transcription

termination and subsequent acquisition of a leader RNA occurs at transcription regulatory

sequences (TRS), located between ORFs. These minus strand subgenomic RNAs serve as

templates for the production of subgenomic mRNAs (Fig. 4), an efficient process that results

in a high ratio of subgenomic mRNA to minus strand subgenomic RNA.[59]

Fig.4: System / Mechanism of replication and transcription of COVID-19.[59]


685


a) Following section into the cell and uncoating, the positive sense RNA genome is meant

produce replicase proteins from open perusing outline 1a/b (ORF1a/b). These proteins

utilize the genome as a format to produce full-length negative sense RNAs, which in this

manner fill in as layouts in creating extra full-length genomes.

b) Coronavirus mRNAs all contain a typical 5′ pioneer arrangement intertwined to

downstream quality successions. These pioneers are included by an intermittent union of

less sense subgenomic RNAs utilizing genome RNA as a format (looked into in Ref. 29).

Subgenomic RNAs are started at the 3′ end of the genome and continue until they

experience one of the transcriptional administrative groupings (TRS; red) that dwell

upstream of most open-understanding casings.

c) Through base-pairing collaborations, the early transcript is moved to the corresponding

pioneer TRS (light red).

d) and translation proceeds through the 5′ end of the genome,

e) These subgenomic RNAs at that point fill in as formats for viral mRNA creation.

Treatment of COVID-19

Current remedies/Medication

Given the absence of successful antiviral treatment against COVID-19, current medicines for

the most part centered around symptomatic and respiratory help as indicated by the Diagnosis

and Treatment of Pneumonia Caused by COVID-19 (refreshed to form 6) gave by National

Health Commission of the People's Republic of China.[60]

About all patients acknowledged

oxygen treatment, and WHO suggested extracorporeal membrane oxygenation (ECMO) to

patients with obstinate hypoxemia.[61]

Salvage treatment with gaining strength plasma and

immunoglobulin G[62,63]

are conveyed to some basic cases as indicated by their conditions.

Antiviral medication

In view of the experience of battling the pandemic SARS-CoV and MERS-CoV beforehand,

we may get familiar with certain exercises for some treatment systems against coronavirus.[64]

Antiviral medications and foundational corticosteroid treatment usually utilized in clinical

practice already, including neuraminidase inhibitors (oseltamivir, peramivir, zanamivir, and

so forth), ganciclovir, acyclovir, and ribavirin, just as methylprednisolone[65,66]

for flu

infection, are invalid for COVID-19 and not prescribed. Remdesivir (GS-5734) is a 1′-cyano-

subbed adenosine nucleotide simple prodrug and shows expansive range antiviral movement

against a few RNA infections. In light of the information gathered from in vitro cell line and


686


mouse model, remdesivir could meddle with the NSP12 polymerase even in the setting of

unblemished ExoN editing action.[67]

Remdesivir has been accounted for to treat the primary

US instance of COVID-19 effectively.[68]

Chloroquine is a repurposed medicate with

extraordinary potential to treat COVID-19. Chloroquine has been utilized to treat intestinal

sickness for a long time.[69]

with a system that isn't surely known against some popular

contaminations. A few potential systems are researched: Chloroquine can restrain pH-

subordinate strides of the replication of a few infections,[70]

with a strong impact on SARS-

CoV contamination and spread.[71]

Besides, chloroquine has immunomodulatory impacts, stifling the creation/arrival or release

of TNF-α and IL-6. It additionally functions as a novel class of autophagy inhibitor,[72]

which

may meddle with viral contamination and replication. A few examinations have discovered

that chloroquine meddled with the glycosylation of cell receptors of SARS-CoV[71]

what's

more, worked at both section and at post-passage phases of the COVID-19 contamination in

Vero E6 cells.[73]

A combo of remdesivir and chloroquine was demonstrated to viably restrain

the as of late rose or inhibit SARS-CoV-2 in vitro. Researchers recently affirmed that the

protease inhibitors lopinavir and ritonavir, used to treat disease with human

immunodeficiency infection (HIV),[74]

could improve the result of MERS-CoV[75]

and SARS-

CoV[76]

patients. It has announced that β-coronavirus viral heaps of a COVID-19 patient in

Korea fundamentally diminished after lopinavir/ritonavir (Kaletra®, AbbVie, North Chicago,

IL, USA) treatment.[77]

Moreover, clinicians joined Chinese and Western medication

treatment including lopinavir/ritonavir (Kaletra®), arbidol, and Shufeng Jiedu Capsule

(SFJDC, a conventional Chinese medication) and increased huge improvement in pneumonia

related indications in Shanghai Public Health Clinical Center, China.[78]

The other antiviral

medications incorporate nitazoxanide, favipiravir, nafamostat, etc.[63]

Neuraminidase inhibitors

Neuraminidase inhibitors are shown in the administration of influenza.[79]

In an examination

on conceivable MERS-CoV cases in Paris from 2013 to 2016, a sum of 35 patients got

oseltamivir (37.6%). In patients positive for flu infection (n = 25), 52% (n = 13) got

oseltamivir and it was reasoned that observational oseltamivir can be begun in presumed

MERS-CoV cases.[80]

Many different investigations likewise assessed oseltamivir in MERS-

CoV.[81]

Oseltamivir was additionally utilized in the administration of 2019-nCoV;


687


notwithstanding, unequivocal proof of adequacy is uncertain in view of absence of

appropriate benchmark group in the studies.[82]

Others medications

Other treatment choices, which are either utilized once in a while or in test state, are SiRNA,

tumor rot factor-alpha inhibitors, killing antibodies, pentoxifylline, and so on., However, the

degree of proof is very poor and subsequently not prescribed for routine consideration.[83]

Recent progress in the treatment of COVID-19

Baricitinib

The SARSCoV and the 2019nCoV both enters host cells through ACE2 receptormediated

entry, especially through AT2 cells present in lungs.[84]

Downstream signaling of this receptor

mediates the endocytosis process, and AP2-associated protein kinase 1 (AAK1) plays a major

role in this process. Thus, AAK1 represents an important target. Richardson et al., 2020

evaluated 378 ligands, of which 47 were already approved for use in other conditions. Among

these ligands, six inhibited AAK1 with high affinity. Considering the side effect profile, they

found janus kinase inhibitor baricitinib to be the most important agent. In addition to AAK1,

baricitinib also binds to another endocytosis regulator protein (cyclin G-associated kinase).

Thus, the authors suggest that baricitinib can be evaluated in the in vitro conditions as well as

in the clinical trial settings for 2019-nCoV.[85,86]

Epidemiology

Cases across World Wide

At present (12 May, 2020) coronavirus cases are 4.18 million, Deaths: 286K, Recovered:

1.46 million. As Graph-1

Graph-1


688


The Impacts of Coronavirus on Economy in India and beyond

The impact of coronavirus is probably going to be seen long after clinical science offers a fix

or possibly an immunization or vaccine. Barclays gauges, that India's forceful 21-day

lockdown could bring the nation's development down to 2.5% from the 4.5% it had before

assessed. A 2019 joint report from the World Health Organization (WHO) and the World

Bank evaluates the effect of such a pandemic at 2.2 percent to 4.8 percent of worldwide GDP

(US$3 trillion). That was well before the world knew about Covid-19. As Prime Minister

Narendra Modi said in his location to the country when he reported a 21-day lockdown, if

this pandemic isn't contained, it could hinder us by decades.

Ben Bernanke, previous administrator of the US Federal Reserve, is significantly more

hopeful. In a TV talk with, Bernanke stated: If there's not all that much harm done to the

workforce, to the organizations during the shutdown time frame, anyway long that perhaps, at

that point we could see a genuinely speedy bounce back.[88]

COVID-19 could influence the

worldwide economy in three primary manners: by legitimately influencing creation, by

making store network and market disturbance (by directly affecting production, by creating

supply chain and market disruption, and by its financial impact), and by its budgetary effect

on firms and money related markets. Nonetheless, an extraordinary arrangement relies upon

the open's response to the malady.

COVID-19 could influence the worldwide economy through three channels

1. Direct impact on production: Chinese creation has just been significantly influenced by

the shutdown in Hubei territory and different territories. Some different nations are

additionally starting to feel an immediate effect as their specialists set up comparable

measures. The stoppage in China has impacts on exporters to China. China's biggest

wellsprings of imports are Korea, Japan, and other Asian nations, as indicated by the

World Bank [89]. Thus, even without new flare-ups of the malady, these zones will

probably encounter moderate development in the primary portion of 2020.

2. Market and supply chain disruption: Many manufacturing firms rely on imported

intermediate inputs from China and other countries affected by the disease. Many

companies rely on sales to meet the financial goals. The slowdown in financial as well as

economic activity and restrictions in transportation in affected countries will likely have

an impact on the production and profitability of specific global companies, mainly in

manufacturing and in raw materials used in manufacturing. For companies that depend on


689


on intermediate goods from affected regions, and that are not able to easily switch

sourcing, the size of the impact may depend on how quickly the outbreak fades. Small

and medium-sized firms may have more difficulty surviving the disruption. Businesses

knotted to travel and tourism are facing losses that are likely not recoverable.

3. Financial impact on firms and financial markets: Impermanent interruptions of

sources of info or potentially creation may pressure a few firms, especially those with

deficient liquidity. Brokers in monetary markets could conceivably effectively foresee or

comprehend which firms may be powerless. The subsequent ascent in hazard may

uncover that at least one key monetary market players have taken speculation places that

are unrewarding under current conditions, further debilitating trust in money related

instruments and markets. A potential (likely low-likelihood) occasion would be a huge

money related market disturbance as members become worried about counterparty

hazard. A to some degree more probable chance is a critical decrease in value markets

and corporate security markets, with financial specialists liking to hold government

protections (especially US treasuries) due to the vulnerability made by the pandemic.

MSME problems under lockdown

Be that as it may, regardless of whether worldwide economies bob back sooner than

anticipated, Indian MSMEs are probably going to follow through on a significant expense.

These organizations are too little to even consider having a sufficient pad to last through a

pandemic like this one. Add to this the way that a considerable lot of these organizations have

been approached to down shades or abridge tasks while as yet paying workers and that is

separated from meeting costs for expenses, power, and different utilities.

The Prime Minister has reported the formation of a financial team to propose a few stages to

facilitate the circumstance.

This is as essential as reinforcing the nation's medicinal services framework. Accessible

information show that MSMEs utilize as much as 110 million individuals; requesting that

organizations continue paying during a drawn out lockdown is anything but an economical

arrangement in the medium-to long haul. Media reports state that MSME delegates have

spoke to the administration for solid action. This incorporates charge concessions, simple

access to credit, GST discounts, and repayment or concession for wage-ensure.[88]

Today

announces the 10% Total GDP of India given to the people.


690


REFERENCES

1. World Health Organization. Household transmission investigation protocol for

coronavirus disease 201 ( COVID-1 ) . World Health Organization; 2020.

2. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and

Treatment Coronavirus (COVID-19). InStat Pearls [Internet] Stat Pearls Publishing,

2020; 3: 8.

3. . Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y.

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for

virus origins and receptor binding. The Lancet, 2020; 22,395(10224): 565-74.

4. ,Wang Q, Wang YH, Ma JC et al. Description of the first strain of 2019-nCoV, C-Tan-

nCoV Wuhan Strain — National Pathogen Resource Center, China, 2020

5. Millet JK, Whittaker GR. Host cell proteases: Critical determinants of coronavirus

tropism and pathogenesis. Virus research, 2015; 16,202: 120-34.

6. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan

JL, Luzuriaga K, Greenough TC, Choe H. Angiotensin-converting enzyme 2 is a

functional receptor for the SARS coronavirus. Nature, 2003; 426(6965): 450-4.

7. Kirchdoerfer RN, Cottrell CA, Wang N, Pallesen J, Yassine HM, Turner HL, Corbett KS,

Graham BS, McLellan JS, Ward AB. Pre-fusion structure of a human coronavirus spike

protein. Nature, 2016; 531(7592): 118-21.

8. Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, Zhong W, Hao P. Evolution of the novel

coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk

of human transmission. Science China Life Sciences, 2020; 63(3): 457-60.

9. Gorbalenya AE. Severe acute respiratory syndrome-related coronavirus–The species and

its viruses, a statement of the Coronavirus Study Group. BioRxiv, 2020; 1.

10. World Health Organization. Director-General's remarks at the media briefing on 2019-

nCoV on, 2020; 02: 21. https://www. who. int/dg/speeches/detail/who-directorgeneral-s-

remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020. 2020.

11. Lam TT, Shum MH, Zhu HC, Tong YG, Ni XB, Liao YS, Wei W, Cheung WY, Li WJ,

Li LF,Leung GM. Identification of 2019-nCoV related coronaviruses in Malayan

pangolins in southern China. BioRxiv, 2020; 1: 1.

12. Zhang L, Shen FM, Chen F, Lin Z. Origin and evolution of the 2019 novel coronavirus.

Clinical Infectious Diseases, 2020; 2: 3.


691


13. Hu D, Zhu C, Ai L, He T, Wang Y, Ye F, Yang L, Ding C, Zhu X, Lv R, Zhu J. Genomic

characterization and infectivity of a novel SARS-like coronavirus in Chinese bats.

Emerging microbes & infections, 2018; 1,7(1): 1-0.

14. General Office of National Health Committee. Office of state administration of

traditional Chinese medicine. Notice on the issuance of a programme for the diagnosis

and treatment of novel coronavirus (2019-nCoV) infected pneumonia (trial fifth edition),

2020; 02: 26.

15. Kanne JP. Chest CT findings in 2019 novel coronavirus (2019-nCoV) infections from

Wuhan, China: key points for the radiologist. Radiology, 2020; 4: 200241.

16. Pan Y, Guan H. Imaging changes in patients with 2019-nCov.

17. Ng MY, Lee EY, Yang J, Yang F, Li X, Wang H, Lui MM, Lo CS, Leung B, Khong PL,

Hui CK. Imaging profile of the COVID-19 infection: radiologic findings and literature

review. Radiology: Cardiothoracic Imaging, 2020; 13.2(1): e200034.

18. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean

NC, Fine MJ, Flanders SA, Griffin MR. Diagnosis and treatment of adults with

community-acquired pneumonia. An official clinical practice guideline of the American

Thoracic Society and Infectious Diseases Society of America. American journal of

respiratory and critical care medicine, 2019; 1.200(7): e45-67.

19. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DS, Du

B. Clinical characteristics of novel coronavirus infection in China. medRxiv, 2019.

20. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y,

Zhao Y. Clinical characteristics of 138 hospitalized patients with 2019 novel

coronavirus–infected pneumonia in Wuhan, China. Jama, 2020; 2: 7.

21. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW,

Tsoi HW. A familial cluster of pneumonia associated with the 2019 novel coronavirus

indicating person-to-person transmission: a study of a family cluster. The Lancet, 2020;

15.395(10223): 514-23.

22. Chen L. Han. Yang F, Zhang tJ, 2001.

23. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The

Lancet, 2020; 15.395(10223): 497-506.

24. Hassan SA, Sheikh FN, Jamal S, Ezeh JK, Akhtar A. Coronavirus (COVID-19): A

Review of Clinical Features, Diagnosis, and Treatment.


692


25. World Health Organization. Clinical management of severe acute respiratory infection

when novel coronavirus (2019-nCoV) infection is suspected, 2019.

At https://www.who.int/csr/disease/coronavirus_infections/InterimGuidance_ClinicalMan

agement_NovelCoronavirus_11Feb13u.pdf?ua=1&ua=1. Accessed February 11, 2020.

26. World Health Organization. WHO guidelines for the global surveillance of severe acute

respiratory syndrome (SARS). 2004.

at https://www.who.int/csr/resources/publications/WHO_CDS_CSR_ARO_2004_1.pdf?u

a=1. Published January, 2004.

27. Azhar EI, El-Kafrawy SA, Farraj SA, Hassan AM, Al-Saeed MS, Hashem AM, Madani

TA. Evidence for camel-to-human transmission of MERS coronavirus. New England

Journal of Medicine, 2014; 26.370(26): 2499-505.

28. General Office of National Health Committee. Office of State Administration of

Traditional Chinese Medicine. Notice on the issuance of a program for the diagnosis and

treatment of novel coronavirus (2019-nCoV) infected pneumonia (trial sixth edition)

(2020-02-19) [EB/OL]. http://yzs.satcm.gov.cn/zhengcewenjian/2020-02-19/13221.html]

29. General Office of National Health Committee. Office of state administration of traditional

Chinese medicine. Notice on the issuance of a programme for the diagnosis and treatment

of novel coronavirus (2019-nCoV) infected pneumonia (trial fifth edition), 2020; 02: 26.

[EB/OL]. http://bgs.satcm.gov.cn/zhengcewenjian/2020-02-06/12847.html

30. World Health Organization. Coronavirus Disease 2019(COVID-19): situation report—28.

2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200217-

sitrep-28-covid-19.pdf?sfvrsn=a19cf2ad_2. Published February, 2020; 18: 20.

31. World Health Organization. Home care for patients with suspected novel coronavirus

(nCoV) infection presenting with mild symptoms and management of contacts

[EB/OL]. https://www.who.int/publications-detail/home-care-for-patients-with-suspected-

novel-coronavirus-(ncov)-infection-presenting-with-mild-symptoms-and-management-of-

contacts. Published January, 2020; 20: 11.

32. Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ, Lu GM, Zhang LJ. Coronavirus disease 2019

(COVID-19): A perspective from China. Radiology, 2020; 21: 200490.

33. Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis.

Nature reviews microbiology, 2009; 7(6): 439-50.

34. Peiris JS, Guan Y, Yuen KY. Severe acute respiratory syndrome. Nature medicine, 2004;

10(12): S88-97.

https://www.who.int/csr/disease/coronavirus_infections/InterimGuidance_ClinicalManagement_NovelCoronavirus_11Feb13u.pdf?ua=1&ua=1

https://www.who.int/csr/disease/coronavirus_infections/InterimGuidance_ClinicalManagement_NovelCoronavirus_11Feb13u.pdf?ua=1&ua=1

https://www.who.int/csr/resources/publications/WHO_CDS_CSR_ARO_2004_1.pdf?ua=1

https://www.who.int/csr/resources/publications/WHO_CDS_CSR_ARO_2004_1.pdf?ua=1

http://yzs.satcm.gov.cn/zhengcewenjian/2020-02-19/13221.html

http://bgs.satcm.gov.cn/zhengcewenjian/2020-02-06/12847.html

https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200217-sitrep-28-covid-19.pdf?sfvrsn=a19cf2ad_2

https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200217-sitrep-28-covid-19.pdf?sfvrsn=a19cf2ad_2

https://www.who.int/publications-detail/home-care-for-patients-with-suspected-novel-coronavirus-(ncov)-infection-presenting-with-mild-symptoms-and-management-of-contacts




693


35. Bárcena M, Oostergetel GT, Bartelink W, Faas FG, Verkleij A, Rottier PJ, Koster AJ,

Bosch BJ. Cryo-electron tomography of mouse hepatitis virus: insights into the structure

of the coronavirion. Proceedings of the National Academy of Sciences, 2009; 13.106(2):

582-7.

36. Neuman BW, Adair BD, Yoshioka C, Quispe JD, Orca G, Kuhn P, Milligan RA, Yeager

M, Buchmeier MJ. Supramolecular architecture of severe acute respiratory syndrome

coronavirus revealed by electron cryomicroscopy. Journal of virology, 2006; 15.80(16):

7918-28.

37. Masters PS. The molecular biology of coronaviruses. Advances in virus research, 2006;

1.66: 193-292.

38. Lissenberg A, Vrolijk MM, Van Vliet AL, Langereis MA, de Groot-Mijnes JD, Rottier

PJ, de Groot RJ. Luxury at a cost? Recombinant mouse hepatitis viruses expressing the

accessory hemagglutinin esterase protein display reduced fitness in vitro. Journal of

virology, 2005; 15.79(24): 15054-63.

39. Lei J, Kusov Y, Hilgenfeld R. Nsp3 of coronaviruses: Structures and functions of a large

multi-domain protein. Antiviral research, 2018; 1.149: 58-74.

40. Song W, Gui M, Wang X, Xiang Y. Cryo-EM structure of the SARS coronavirus spike

glycoprotein in complex with its host cell receptor ACE2. PLoS pathogens, 2018;

13.14(8): e1007236.

41. Angeletti S, Benvenuto D, Bianchi M, Giovanetti M, Pascarella S, Ciccozzi M. COVID-

2019: The role of the nsp2 and nsp3 in its pathogenesis. J. Med. Virol, 2020; 2: 21.

42. Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary pathology of early phase 2019

novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. Journal of

Thoracic Oncology, 2020; 2: 28.

43. Ning Q, Lakatoo S, Liu M, Yang W, Wang Z, Phillips MJ, Levy GA. Induction of

prothrombinase fgl2 by the nucleocapsid protein of virulent mouse hepatitis virus is

dependent on host hepatic nuclear factor-4α. Journal of Biological Chemistry, 2003;

2.278(18): 15541-9.

44. Zhao X, Nicholls JM, Chen YG. Severe acute respiratory syndrome-associated

coronavirus nucleocapsid protein interacts with Smad3 and modulates transforming

growth factor-β signaling. Journal of Biological Chemistry, 2008; 8.283(6): 3272-80.

45. DeDiego ML, Álvarez E, Almazán F, Rejas MT, Lamirande E, Roberts A, Shieh WJ,

Zaki SR, Subbarao K, Enjuanes L. A severe acute respiratory syndrome coronavirus that


694


lacks the E gene is attenuated in vitro and in vivo. Journal of virology, 2007; 15.81(4):

1701-13.

46. Kuo L, Masters PS. The small envelope protein E is not essential for murine coronavirus

replication. Journal of virology, 2003; 15.77(8): 4597-608.

47. Ortego J, Ceriani JE, Patiño C, Plana J, Enjuanes L. Absence of E protein arrests

transmissible gastroenteritis coronavirus maturation in the secretory pathway. Virology,

2007; 25.368(2): 296-308.

48. Madan V, de Jesús García M, Sanz MA, Carrasco L. Viroporin activity of murine

hepatitis virus E protein. FEBS letters, 2005; 4.579(17): 3607-12.

49. Wilson L, Mckinlay C, Gage P, Ewart G. SARS coronavirus E protein forms cation-

selective ion channels. Virology, 2004; 5.330(1): 322-31.

50. Yount B, Roberts RS, Sims AC, Deming D, Frieman MB, Sparks J, Denison MR, Davis

N, Baric RS. Severe acute respiratory syndrome coronavirus group-specific open reading

frames encode nonessential functions for replication in cell cultures and mice. Journal of

virology, 2005; 15.79(23): 14909-22.

51. Ontiveros E, Kuo L, Masters PS, Perlman S. Inactivation of expression of gene 4 of

mouse hepatitis virus strain JHM does not affect virulence in the murine CNS. Virology,

2001; 25.289(2): 230-8.

52. de Haan CA, Masters PS, Shen X, Weiss S, Rottier PJ. The group-specific murine

coronavirus genes are not essential, but their deletion, by reverse genetics, is attenuating

in the natural host. Virology, 2002; 25.296(1): 177-89.

53. Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, Wang H, Crameri G, Hu Z, Zhang H,

Zhang J. Bats are natural reservoirs of SARS-like coronaviruses. Science, 2005;

28.310(5748): 676-9.

54. Fischer F, Peng D, Hingley ST, Weiss SR, Masters PS. The internal open reading frame

within the nucleocapsid gene of mouse hepatitis virus encodes a structural protein that is

not essential for viral replication. Journal of virology, 1997; 1.71(2): 996-1003.

55. Huang C, Peters CJ, Makino S. Severe acute respiratory syndrome coronavirus accessory

protein 6 is a virion-associated protein and is released from 6 protein-expressing cells.

Journal of virology, 2007; 15.81(10): 5423-6.

56. Ito N, Mossel EC, Narayanan K, Popov VL, Huang C, Inoue T, Peters CJ, Makino S.

Severe acute respiratory syndrome coronavirus 3a protein is a viral structural protein.



695


57. Schaecher SR, Mackenzie JM, Pekosz A. The ORF7b protein of severe acute respiratory

syndrome coronavirus (SARS-CoV) is expressed in virus-infected cells and incorporated

into SARS-CoV particles. Journal of virology, 2007; 15.81(2): 718-31.

58. Neuman BW, Joseph JS, Saikatendu KS, Serrano P, Chatterjee A, Johnson MA, Liao L,

Klaus JP, Yates JR, Wüthrich K, Stevens RC. Proteomics analysis unravels the functional

repertoire of coronavirus nonstructural protein 3. Journal of virology, 2008; 1.82(11):

5279-94.

59. Sawicki SG, Sawicki DL, Siddell SG. A contemporary view of coronavirus transcription.


60. National Health Commission of the People’s Republic of China. Diagnosis and Treatment

of Pneumonia Caused by 2019-nCoV (version 6).

2020. http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm.

Accessed 18 Feb 2020.Return to ref 71 in article

61. WHO. Clinical management of severe acute respiratory infection when novel coronavirus

(nCoV) infection is suspected. https://www.who.int/publications-detail/clinical-

management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-

infection-is-suspected, 2020; 28: 1.

62. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-

19. The Lancet Infectious Diseases, 2020; 1.20(4): 398-400.

63. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. The

origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19)

outbreak–an update on the status. Military Medical Research, 2020; 7(1): 1-0.

64. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses—drug discovery and

therapeutic options. Nature reviews Drug discovery, 2016; 15(5): 327.

65. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138

hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China.

JAMA. 2020. https://doi.org/10.1001/jama.2020; 1585.

66. Li H, Wang YM, Xu JY, Cao B. Potential antiviral therapeutics for 2019 Novel

Coronavirus. Zhonghua jie he he hu xi za zhi= Zhonghua jiehe he huxi zazhi= Chinese

journal of tuberculosis and respiratory diseases, 2020; 5.43: E002.

67. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB,

Feng JY, Jordan R, Ray AS. Coronavirus susceptibility to the antiviral remdesivir (GS-

5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio.

2018; 2.(2): e00221-18.

http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm

https://link.springer.com/article/10.1186/s40779-020-00240-0#ref-link-section-d11785e1438

https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected



https://doi.org/10.1001/jama.2020;%201585


696


68. https://doi.org/10.1128/mBio.00221-18.

69. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of

2019 novel coronavirus in the United States. N Engl J Med.

2020. https://doi.org/10.1056/NEJMoa2001191

70. Aguiar ACC, Murce E, Cortopassi WA, Pimentel AS, Almeida M, Barros DCS, et al.

Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity.

Int J Parasitol Drugs Drug Resist, 2018; 8(3): 459–64.

71. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral

infections: an old drug against today's diseases? Lancet Infect Dis, 2003; 3(11): 722–7.

72. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al.

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J.,

2005; 2: 69.

73. Golden EB, Cho HY, Hofman FM, Louie SG, Schonthal AH, Chen TC. Quinoline-based

antimalarial drugs: a novel class of autophagy inhibitors. Neurosurg Focus, 2015; 38(3):

E12.

74. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G.

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus

(2019-nCoV) in vitro. Cell research, 2020; 30(3): 269-71.

75. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of

HIV infection. Drugs, 2003; 63(8): 769–802.

76. Arabi YM, Asiri AY, Assiri AM, Jokhdar HA, Alothman A, Balkhy HH, AlJohani S, Al

Harbi S, Kojan S, Al Jeraisy M, Deeb AM. Treatment of Middle East respiratory

syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial):

statistical analysis plan for a recursive two-stage group sequential randomized controlled

trial. Trials, 2020; 21(1): 1-8.

77. Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. Role of

lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.

Thorax, 2004; 59(3): 252–6.

78. Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the index patient

who caused tertiary transmission of COVID-19 infection in Korea: the application of

lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by

quantitative RT-PCR. J Korean Med Sci, 2020; 35(6): e79.

79. Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic

procedure for four cases with 2019 novel coronavirus pneumonia receiving combined

https://doi.org/10.1128/mBio.00221-18

https://doi.org/10.1056/NEJMoa2001191


697


Chinese and Western medicine treatment. Biosci Trends.

2020. https://doi.org/10.5582/bst.2020.01030

80. Neuraminidase inhibitors for treatment of influenza A and B infections. MMWR

Recomm Rep, 1999; 48: 1–9.

81. Bleibtreu A, Jaureguiberry S, Houhou N, Boutolleau D, Guillot H, Vallois D, Lucet JC,

Robert J, Mourvillier B, Delemazure J, Jaspard M. Clinical management of respiratory

syndrome in patients hospitalized for suspected Middle East respiratory syndrome

coronavirus infection in the Paris area from 2013 to 2016. BMC infectious diseases, 2018,

1.18(1): 331.

82. Al-Abdely HM, Midgley CM, Alkhamis AM, Abedi GR, Lu X, Binder AM, Alanazi KH,

Tamin A, Banjar WM, Lester S, Abdalla O. Middle East respiratory syndrome

coronavirus infection dynamics and antibody responses among clinically diverse patients,

Saudi Arabia. Emerging Infectious Diseases, 2019; 25(4): 753.

83. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, ssCheng Z.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The

Lancet, 2020; 15.395(10223): 497-506.

84. Tai DY. Pharmacologic treatment of SARS: current knowledge and recommendations.

ANNALS-ACADEMY OF MEDICINE SINGAPORE, 2007; 1.36(6): 438.

85. Hoffmann M, Kleine-Weber H, Krüger N, Mueller MA, Drosten C, Pöhlmann S. The

novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the

cellular protease TMPRSS2 for entry into target cells. BioRxiv, 2020; 1.

86. Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as

potential treatment for 2019-nCoV acute respiratory disease. Lancet.

87. Sarma P, Prajapat M, Avti P, Kaur H, Kumar S, Medhi B. Therapeutic options for the

treatment of 2019-novel coronavirus: An evidence-based approach. Indian Journal of

Pharmacology, 2020; 52(1): 1.

88. https://www.worldometers.info/coronavirus/?utm_campaign=homeAdvegas1?

89. https://www.indiatoday.in/news-analysis/story/trade-in-the-time-of-covid-19-the-

economic-impact-of-coronavirus-on-india-and-beyond-1661118-2020-03-29

90. World Bank, ―World integrated trade solution,‖ accessed March 2, 2020.

https://www2.deloitte.com/us/en/insights/economy/covid-19/economic-impact-covid-

19.html

https://doi.org/10.5582/bst.2020.01030

https://www.worldometers.info/coronavirus/?utm_campaign=homeAdvegas1?

https://www.indiatoday.in/news-analysis/story/trade-in-the-time-of-covid-19-the-economic-impact-of-coronavirus-on-india-and-beyond-1661118-2020-03-29

https://www.indiatoday.in/news-analysis/story/trade-in-the-time-of-covid-19-the-economic-impact-of-coronavirus-on-india-and-beyond-1661118-2020-03-29

https://wits.worldbank.org/Default.aspx?lang=en

https://www2.deloitte.com/us/en/insights/economy/covid-19/economic-impact-covid-19.html

https://www2.deloitte.com/us/en/insights/economy/covid-19/economic-impact-covid-19.html

Documents

WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL …